Use of Off-Label Drugs and Nutrition Supplements among Patients with Amyotrophic Lateral Sclerosis in Norway
Open Access
- 12 April 2022
- journal article
- research article
- Published by Hindawi Limited in Neurology Research International
- Vol. 2022, 1-6
Abstract
Background and Objectives. Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease, characterized by gradual paralysis and muscle atrophy. Riluzole, the only approved treatment in Norway, increases mean survival by 36 months. The use of off-label medications and nutritional supplements is common in other serious conditions, such as Parkinsons disease and dementia. The aims of this study were to investigate to what extent Norwegian ALS patients use supplements and off-label medications and whether this is related to their health-related quality-of-life (HRQOL). Materials and Methods. A cross-sectional questionnaire study was performed, where 41 ALS patients reported their use of off-label treatments, as well as self-perceived HRQOL using the RAND-12 questionnaire. Results. A majority of respondents used riluzole. Of the 41 respondents, 18 (43.9) reported use of off-label medications and 18 (43.9) used nutritional supplements. Low-dose naltrexone was the most commonly used off-label medication, whereas vitamins accounted for most of the nutritional supplements. The respondents RAND-12 component scores were significantly lower than those of the general population. Low-dose naltrexone and vitamin B were associated with a better physical component score. Conclusions. Most of the respondents in our study adhere to the recommended treatment protocols, as less than half of them reported using off-label medications or nutritional supplements against ALS. Positive correlations between physical HRQOL and use of low-dose naltrexone or vitamin B were demonstrated. These results warrant further investigations.Keywords
This publication has 45 references indexed in Scilit:
- Cognitive impairment and vitamin B12: a reviewInternational Psychogeriatrics, 2012
- Clinical diagnosis and management of amyotrophic lateral sclerosisNature Reviews Neurology, 2011
- ALSUntangled No. 8: Low dose naltrexone for ALSAmyotrophic Lateral Sclerosis, 2010
- ALSUntangled (ALSU): A Scientific Approach to Off-Label Treatment Options for People with ALS Using Tweets and TwittersAmyotrophic Lateral Sclerosis, 2009
- Consequences of Using SF-12 and RAND-12 when Examining Levels of Well-Being and Psychological DistressAustralian & New Zealand Journal of Psychiatry, 2008
- Use of nutritional supplements in Parkinson's disease patientsMovement Disorders, 2006
- Multidisciplinary ALS care improves quality of life in patients with ALSNeurology, 2005
- The Use of Herbal Supplements and Alternative Therapies by Patients with Amyotrophic Lateral Sclerosis (ALS)Journal of Herbal Pharmacotherapy, 2005
- Assessing health status quality of life in ALS: Comparison of the SIP/ALS-19 with the ALS Functional Rating Scale and the Short Form-12 Health SurveyAmyotrophic Lateral Sclerosis, 2001
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994